Incyte Corp (INCY)

$91.28 +1.97 (2.21%)
Market Cap 17.44B
Revenue (ttm) 4.24B
Net Income (ttm) 32.61M
EPS (ttm) N/A
PE Ratio 21.91
Forward PE 17.14
Profit Margin 0.77%
Debt to Equity Ratio 0.00
Volume 2,236,700
Avg Vol 1,746,370
Day's Range N/A - N/A
Shares Out 195.28M
Stochastic %K 83%
Beta 0.73
Analysts Sell
Price Target $86.38

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
JFDI
JFDI Oct. 24 at 7:53 PM
$INCY B/O
0 · Reply
JFais
JFais Oct. 24 at 5:49 PM
$SNDX- Compare $1B+ peak sales potential for Revuforj in r/r AML alone to current $800M EV Not to event mention $INCY/Niktimvo contribution I could be off, but how I see it
0 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:40 PM
$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
1 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:35 PM
$AGEN & $INCY INCY needs to buy Agenus! New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
0 · Reply
JFais
JFais Oct. 24 at 5:10 PM
$SNDX- no need to revisit PTs as of yet, still more to prove (clock ticking for $INCY though if doesn't want to overpay for full Niktimvo rights)
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:29 PM
$INCY set for an earnings beat? With a +3.48% Earnings ESP and a Zacks Rank #3, $INCY is poised to surpass expectations for its Q3 2025 earnings. Jakafi's strong sales and promising royalty revenues could fuel this momentum. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-body-17533&ADID=SYND_STOCKTWITS_TWEET_2_2776437_BODY_17533
0 · Reply
Doozio
Doozio Oct. 24 at 2:45 PM
The $INCY wincy makes it up da water spout on FRYdays during 🐒🍌🧠⏰♾️
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 2:29 PM
$INCY gearing up for a potential earnings surprise? Jakafi, Opzelura, and the new Niktimvo launch are expected to fuel solid Q3 revenue growth — setting the stage for a possible beat. Full earnings preview here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-teaser-17512&ADID=SYND_STOCKTWITS_TWEET_2_2776437_TEASER_17512
0 · Reply
StockConsultant
StockConsultant Oct. 24 at 12:15 PM
$INCY Incyte stock, good close and top of range breakout
0 · Reply
pilobious
pilobious Oct. 24 at 12:11 PM
$INCY pre market buying. Very unusual for this stock. I’ve seen the market ignore FDA approval for INCY pre market. Earnings will be strong Tuesday morning.
0 · Reply
Latest News on INCY
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

Oct 24, 2025, 6:45 AM EDT - 1 day ago

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial

LLY

Incyte: Strong Growth, Margin Expansion, And Low Valuation

Oct 21, 2025, 11:13 PM EDT - 3 days ago

Incyte: Strong Growth, Margin Expansion, And Low Valuation

Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript

Oct 20, 2025, 5:24 PM EDT - 4 days ago

Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

Oct 19, 2025, 1:30 PM EDT - 5 days ago

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma

3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 9 days ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY SNDX XBI

Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

Oct 12, 2025, 6:05 PM EDT - 12 days ago

Data from Incyte's TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025

Incyte to Report Third Quarter Financial Results

Oct 8, 2025, 8:00 AM EDT - 17 days ago

Incyte to Report Third Quarter Financial Results

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

Sep 28, 2025, 12:20 AM EDT - 27 days ago

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 24, 2025, 4:30 PM EDT - 4 weeks ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cramer reveals 5 undervalued stocks that are must-own heading into 2026

Sep 24, 2025, 3:15 PM EDT - 4 weeks ago

Cramer reveals 5 undervalued stocks that are must-own heading into 2026

AXP CAT DLTR TMUS

Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher

Sep 22, 2025, 6:46 PM EDT - 4 weeks ago

Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher

DELL DLTR EXPE TMUS APO AXP BXP

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

Sep 22, 2025, 7:30 AM EDT - 4 weeks ago

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 5 weeks ago

3 Potential Biotech Acquisition Targets

AZN ETNB MLYS SNDX TVTX

US FDA approves Incyte's eczema treatment for pediatric patients

Sep 18, 2025, 4:29 PM EDT - 5 weeks ago

US FDA approves Incyte's eczema treatment for pediatric patients

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Sep 18, 2025, 4:21 PM EDT - 5 weeks ago

Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Sep 17, 2025, 1:00 AM EDT - 5 weeks ago

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress

Sep 10, 2025, 7:30 AM EDT - 6 weeks ago

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Sep 9, 2025, 2:22 PM EDT - 6 weeks ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

CRSP XBI XLV

Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 1:46 PM EDT - 6 weeks ago

Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 4:13 PM EDT - 7 weeks ago

Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 11:38 AM EDT - 7 weeks ago

Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Sep 3, 2025, 9:15 AM EDT - 7 weeks ago

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa

Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio

Aug 30, 2025, 9:30 AM EDT - 7 weeks ago

Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

Aug 25, 2025, 8:00 AM EDT - 2 months ago

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

Incyte to Present at Upcoming Investor Conferences

Aug 19, 2025, 8:00 AM EDT - 2 months ago

Incyte to Present at Upcoming Investor Conferences

20 stocks in the S&P 500 that are high achievers this earnings season

Aug 15, 2025, 8:52 AM EDT - 2 months ago

20 stocks in the S&P 500 that are high achievers this earnings season

ANET APH COIN CTRA EQT EXE FICO

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

Jul 31, 2025, 4:30 PM EDT - 3 months ago

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 1:33 PM EDT - 3 months ago

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Jul 29, 2025, 11:13 AM EDT - 3 months ago

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Jul 29, 2025, 8:30 AM EDT - 3 months ago

Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

Jul 24, 2025, 5:02 PM EDT - 3 months ago

Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

Incyte to Report Second Quarter Financial Results

Jul 10, 2025, 8:00 AM EDT - 3 months ago

Incyte to Report Second Quarter Financial Results

Incyte: New CEO Brings A New Possible Outcome

Jul 3, 2025, 6:11 AM EDT - 4 months ago

Incyte: New CEO Brings A New Possible Outcome

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Jun 26, 2025, 7:30 AM EDT - 4 months ago

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Incyte Says FDA Extended Review Period for Opzelura

Jun 20, 2025, 5:10 PM EDT - 4 months ago

Incyte Says FDA Extended Review Period for Opzelura

Incyte Lymphoma Treatment Gets FDA Approval

Jun 18, 2025, 4:12 PM EDT - 4 months ago

Incyte Lymphoma Treatment Gets FDA Approval

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Jun 18, 2025, 3:39 PM EDT - 4 months ago

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Jun 15, 2025, 4:00 AM EDT - 4 months ago

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QGEN

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Jun 15, 2025, 3:15 AM EDT - 4 months ago

Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Jun 12, 2025, 6:45 PM EDT - 4 months ago

Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2025, 4:30 PM EDT - 5 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

Jun 3, 2025, 10:30 AM EDT - 5 months ago

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

Jun 2, 2025, 12:15 PM EDT - 5 months ago

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

AIG APTV BALL CTRA DELL DVA ELV

Incyte to Present at Upcoming Investor Conference

May 27, 2025, 8:00 AM EDT - 5 months ago

Incyte to Present at Upcoming Investor Conference

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

May 15, 2025, 2:30 PM EDT - 5 months ago

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

JFDI
JFDI Oct. 24 at 7:53 PM
$INCY B/O
0 · Reply
JFais
JFais Oct. 24 at 5:49 PM
$SNDX- Compare $1B+ peak sales potential for Revuforj in r/r AML alone to current $800M EV Not to event mention $INCY/Niktimvo contribution I could be off, but how I see it
0 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:40 PM
$AGEN & $INCY, $LLY INCY needs to buy needs to buy Agen LLY needs to buy INCY New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
1 · Reply
2_logs_higher
2_logs_higher Oct. 24 at 5:35 PM
$AGEN & $INCY INCY needs to buy Agenus! New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful hair regrowth on the scalp, eyebrows and eyelashes at one year. Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) https://finance.yahoo.com/news/lillys-baricitinib-delivered-near-complete-104500483.html?guccounter=1
0 · Reply
JFais
JFais Oct. 24 at 5:10 PM
$SNDX- no need to revisit PTs as of yet, still more to prove (clock ticking for $INCY though if doesn't want to overpay for full Niktimvo rights)
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:29 PM
$INCY set for an earnings beat? With a +3.48% Earnings ESP and a Zacks Rank #3, $INCY is poised to surpass expectations for its Q3 2025 earnings. Jakafi's strong sales and promising royalty revenues could fuel this momentum. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-body-17533&ADID=SYND_STOCKTWITS_TWEET_2_2776437_BODY_17533
0 · Reply
Doozio
Doozio Oct. 24 at 2:45 PM
The $INCY wincy makes it up da water spout on FRYdays during 🐒🍌🧠⏰♾️
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 2:29 PM
$INCY gearing up for a potential earnings surprise? Jakafi, Opzelura, and the new Niktimvo launch are expected to fuel solid Q3 revenue growth — setting the stage for a possible beat. Full earnings preview here 👉 https://www.zacks.com/stock/news/2776437/incyte-gears-up-to-report-q3-earnings-is-a-beat-in-the-cards?cid=sm-stocktwits-2-2776437-teaser-17512&ADID=SYND_STOCKTWITS_TWEET_2_2776437_TEASER_17512
0 · Reply
StockConsultant
StockConsultant Oct. 24 at 12:15 PM
$INCY Incyte stock, good close and top of range breakout
0 · Reply
pilobious
pilobious Oct. 24 at 12:11 PM
$INCY pre market buying. Very unusual for this stock. I’ve seen the market ignore FDA approval for INCY pre market. Earnings will be strong Tuesday morning.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 24 at 11:08 AM
WATCHLIST OCT 24 2025 $NVDA Schneider Electric Reaffirms Commitment To Supporting 800 VDC Infrastructure For Next-Gen High-Density Rack Architectures $GNTA Genenta Science Teams With Anemocyte To Enhance Off-The-Shelf Lentiviral Vector Plasmid DNA Platform Providing Reliable Materials From Preclinical To Commercial Applications $SEED Origin Agritech Receives New Crop Seed Production And Operation License From Beijing Municipal Bureau Of Agriculture And Rural Affairs $INCY Eli Lilly And Incyte's Baricitinib Delivers One-Year Hair Regrowth In Adolescents With Severe Alopecia Areata; BRAVE-AA-PEDS Data To Be Presented At 2025 FCD Conference $LNT UBS Upgrades Alliant Energy to Buy, Raises Price Target to $79
0 · Reply
StockHunter75
StockHunter75 Oct. 23 at 2:40 PM
$INCY Bullish
0 · Reply
zman94
zman94 Oct. 22 at 10:40 PM
https://seekingalpha.com/article/4831678?gt=492e161a7d50b892 $INCY
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 3:29 PM
$INCY Share Price: $86.85 Contract Selected: Mar 20, 2026 $90 Calls Buy Zone: $5.95 – $7.35 Target Zone: $10.51 – $12.85 Potential Upside: 67% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 1:57 PM
Enter: $INCY NOV 21 2025 $88 CALLS Buy in Price: $4.00 - $4.20 Take Profit: $7.76 Stop Bleeding: $3.52 ROI Potential: 94% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
Doozio
Doozio Oct. 20 at 7:11 PM
$INCY bahhht them MNDY 🐑 🎁 s?
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 3:02 PM
Enter: $INCY NOV 21 2025 $90 CALLS Buy in Price: $3.85 - $5.50 Take Profit: $8.43 Stop Bleeding: $3.39 ROI Potential: 119% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
Varlamovnyse
Varlamovnyse Oct. 18 at 6:59 PM
$INCY strong fundamentals
0 · Reply
nikitatrades
nikitatrades Oct. 17 at 12:30 PM
Health Canada approves Incyte's $INCY Opzelura cream for treating atopic dermatitis in children aged 2+. This is the product's 3rd Canadian approval.
0 · Reply
pilobious
pilobious Oct. 17 at 3:43 AM
$INCY Incyte worth $164 on discounted cash flow basis. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/a-look-at-incytes-valuation-following-positive-early-data-fo
0 · Reply
Doozio
Doozio Oct. 16 at 11:56 PM
Da $INCY wincy spider shud not climb up da water spout on a 🐑 Thursday!
0 · Reply
OptionRunners
OptionRunners Oct. 16 at 2:27 PM
$INCY December 19th $85P/$72.50P/$100C bear seagulls opening 3,000 times for no cost ahead of earnings on 10/28
0 · Reply